Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Medicine and Dentistry New Jersey Bayer |
---|---|
Information provided by: | University of Medicine and Dentistry New Jersey |
ClinicalTrials.gov Identifier: | NCT00468182 |
The purpose of this study is to determine whether interferon-beta impairs the ability of plasmacytoid dendritic cells to promote pathogenic immune responses in patients with multiple sclerosis.
Condition | Intervention | Phase |
---|---|---|
Multiple Sclerosis |
Drug: Interferon-beta 1b (Betaseron) |
Phase IV |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis |
Estimated Enrollment: | 24 |
Study Start Date: | April 2007 |
Groups/Cohorts | Assigned Interventions |
---|---|
1
MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)
|
Drug: Interferon-beta 1b (Betaseron)
Treatment of patients with FDA-approved Rx
|
2
MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta
|
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Multiple Sclerosis Clinic patient
Inclusion Criteria:
Exclusion Criteria:
Contact: Konstantin Balashov, M.D., Ph.D. | 732-235-7340 | balashke@umdnj.edu |
United States, New Jersey | |
UMDNJ-Robert Wood Johnson Medical School | Recruiting |
New Brunswick, New Jersey, United States, 08901 | |
Contact: Konstantin Balashov, M.D., Ph.D. 732-235-7732 balashke@umdnj.edu |
Principal Investigator: | Konstantin Balashov, M.D., Ph.D. | University of Medicine and Dentistry New Jersey |
Responsible Party: | UMDNJ ( Konstantin Balashov, MD, PhD ) |
Study ID Numbers: | 0220060228 |
Study First Received: | April 30, 2007 |
Last Updated: | June 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00468182 |
Health Authority: | United States: Institutional Review Board |
Multiple sclerosis Interferon beta plasmacytoid dendritic cells |
Autoimmune Diseases Multiple Sclerosis Demyelinating Diseases Interferons Interferon beta-1b |
Interferon-beta Demyelinating Autoimmune Diseases, CNS Demyelinating diseases Sclerosis Autoimmune Diseases of the Nervous System |
Anti-Infective Agents Pathologic Processes Immunologic Factors Immune System Diseases Antineoplastic Agents Therapeutic Uses |
Physiological Effects of Drugs Nervous System Diseases Adjuvants, Immunologic Antiviral Agents Pharmacologic Actions |